SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Govt extends Schedule M implementation deadline for small, medium pharma firms till Dec 31

13 Feb 2025 Evaluate

The Ministry of Health & Family Welfare has extended the due date for implementation of revised Schedule M -- good manufacturing practices provision, for small and medium pharmaceutical firms with turnover of Rs 250 crore or less, till December 31, 2025. It has given three months from February 11, 2025, to the small and medium pharmaceutical firms to submit their plan for upgradation to the central license approving authority in order to be eligible to qualify for Schedule M deadline extension. 

The ministry said on December 28, 2023, the Centre notified revised 'Schedule M' requirements wherein ‘good manufacturing practices’ was upgraded to ‘good manufacturing practices and requirements of plan and equipment for pharmaceutical products’. Under this, manufacturers were divided into two groups with the first category of large manufacturers having turnover more than Rs 250 crore. A timeline of six months was given to such manufacturers for compliance and the revised Schedule M requirements have been implemented for these manufacturers from June 28, 2024. 

For small and medium manufacturers with turnover less than or equal to Rs 250 crore, a timeline of 12 months was given for compliance. Small and medium manufacturers had represented for extension of timeline to enable improvement in infrastructure, training of personnel and arranging financial resources. It said the revised Schedule M requirements are a positive step towards ensuring the quality and safety of pharmaceutical products being manufactured in India. The new regulations would enable the pharma companies to not only strengthen their domestic position but also become more competitive globally. 


About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×